Tomer M. Mark

Dr. Tomer M. Mark

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2023 in Journal of Clinical Oncology
Verified
Journal Article
Open access
PSPieter Sonneveld
Pieter Sonneveld
ACAsher Chanan-Khan
Asher Chanan-Khan
KWKatja Weisel
Katja Weisel
ANAjay K. Nooka
Ajay K. Nooka
TMTamás Masszi
Tamás Masszi
Andrew SpencerAndrew Spencer
Andrew Spencer
PURPOSE: At the primary analysis of CASTOR (median follow-up, 7.4 months), daratumumab plus bortezomib and dexamethasone (D-Vd) significantly prolonged progression-free survival versus bortezomib and dexamethasone (Vd) alone in relapsed or refractory multiple myeloma (RRMM). We report updated efficacy and safety results at the final analysis for overall survival (OS). METHODS: CASTOR was a multicenter, randomized, open-label, phase III study during which eligible patients with ≥ 1 line of prior therapy were randomly assigned to Vd (up to eight cycles) with or without daratumumab (until disease progression). After positive primary analysis and protocol amendment, patients receiving Vd were offered daratumumab monotherapy after disease progression. RESULTS: At a median (range) follow-up of 72.6 months (0.0-79.8), significant OS benefit was observed with D-Vd (hazard ratio, 0.74; 95% CI, 0.59 to 0.92; P = .0075). Median OS was 49.6 months with D-Vd versus 38.5 months with Vd. Prespecified subgroup analyses demonstrated an OS advantage with D-Vd versus Vd for most subgroups, including patients age ≥ 65 years and patients with one or two prior lines of therapy, International Staging System stage III disease, high-risk cytogenetic abnormalities, and prior bortezomib treatment. The most common (≥ 10%) grade 3/4 treatment-emergent adverse events with D-Vd versus Vd were thrombocytopenia (46.1% v 32.9%), anemia (16.0% v 16.0%), neutropenia (13.6% v 4.6%), lymphopenia (10.3% v 2.5%), and pneumonia (10.7% v 10.1%). CONCLUSION: D-Vd significantly prolonged OS in patients with RRMM, with the greatest OS benefit observed in patients with one prior line of therapy. To our knowledge, our results, together with the OS benefit observed with daratumumab plus lenalidomide and dexamethasone in the phase III POLLUX study, demonstrate for the first time an OS benefit with daratumumab-containing regimens in RRMM (ClinicalTrials.gov identifier: NCT02136134 [CASTOR]).

1 June 2017 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
TMTomer M. Mark
Tomer M. Mark
DGDanielle Guarneri
Danielle Guarneri
PFPeter Forsberg
Peter Forsberg
ARAdriana Rossi
Adriana Rossi
RPRoger Pearse
Roger Pearse
RNRuben Niesvizky
Ruben Niesvizky
Autologous stem cell transplantation (ASCT) conditioned with high-dose chemotherapy has long been established as the standard of care for eligible patients with newly diagnosed multiple myeloma. Despite recent therapeutic advances, high-dose melphalan (HDM) remains the chemotherapy regimen of choice in this setting. Lenalidomide (LEN) in combination with low-dose dexamethasone is recognized as a standard of care for patients with relapsed or refractory multiple myeloma (RRMM), and there is growing support for the administration of LEN as maintenance therapy post-ASCT. In view of the above, the present phase I clinical trial was designed to evaluate the safety and tolerability of high-dose LEN (HDLEN) in patients with RRMM, and to determine the maximum tolerated dose of HDLEN when added to HDM before ASCT. Despite administering HDLEN at doses of up to 350 mg/day, the maximum tolerated dose could not be determined, owing to an insufficient number of dose-limiting toxicities in the 21 patients enrolled in the trial. Conditioning with HDLEN plus HDM was associated with a favorable tolerability profile. Adverse events following ASCT were as expected with HDM. Median progression-free and overall survival were 10 months and 22 months, respectively, in this population of heavily pretreated patients. Our findings suggest that HDLEN in combination with HDM may offer significant potential as a conditioning regimen before ASCT in patients with RRMM. These preliminary findings are now being evaluated further in an ongoing phase II clinical trial.

1 December 2020 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
ACAnne Strong Caldwell
Anne Strong Caldwell
MHMichael Huvard
Michael Huvard
JOJeffrey L. Olson
Jeffrey L. Olson
TMTomer M. Mark
Tomer M. Mark
CYCara E. Capitena Young
Cara E. Capitena Young

10 February 2019 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
PFPeter A. Forsberg
Peter A. Forsberg
ARAdriana C. Rossi
Adriana C. Rossi
ABAngelique Boyer Bs
Angelique Boyer Bs
LTLinda Tegnestam
Linda Tegnestam
RPRoger N. Pearse
Roger N. Pearse
TMTomer M. Mark
Tomer M. Mark

17 November 2021 in Future Oncology
Verified
Journal Article
Open access
TMTomer M. Mark
Tomer M. Mark
AFAngelica Falkenstein
Angelica Falkenstein
JKJonathan Kish
Jonathan Kish
Aim: To demonstrate the efficacy of pomalidomide for relapsed/refractory multiple myeloma (RRMM) following treatment in real-world, community practice using retrospective database analysis. Materia... Plain language summary Treatment options have expanded in recent years for patients with relapsed/refractory multiple myeloma (RRMM) who received lenalidomide as their initial treatment and then ei...

2 December 2016 in Blood
Verified
Journal Article
Open access
PFPeter A. Forsberg
Peter A. Forsberg
ARAdriana Rossi
Adriana Rossi
RPRoger N Pearse
Roger N Pearse
APArthur Perry
Arthur Perry
KPKaren Pekle
Karen Pekle
TMTomer M. Mark
Tomer M. Mark
Background- Currently combination regimens for induction therapy based around a proteasome inhibitor (PI), an immunomodulatory agent (IMiD) or both are standard for the treatment of newly diagnosed multiple myeloma (NDMM). In phase II studies the combination of Carfilzomib, Lenalidomide and Dexamethasone (Dex) has led to very high rates of overall and deep responses as induction therapy (Jakubowiak Blood 2012). According to the Norton-Simon hypothesis, the sequential, dose-dense use of agents that are not cross-resistant and have minimal overlapping toxicity may eliminate the emergence of residual inherently resistant sub-clones which are responsible for relapse. A sequential approach may also allow for medications to be administered at higher doses and the incorporation of more active agents into an initial therapeutic platform than can be tolerated in a single combinatorial induction approach. To date limited research has been done which evaluates a planned sequential therapeutic protocol built around the successive administration of a highly active PI and IMiD for NDMM. We conducted a phase II study evaluating high dose Carfilzomib and Dex induction (Kd) followed by Lenalidomide, clarithromycin and Dex (BiRD) consolidation and Lenalidomide maintenance in NDMM to evaluate safety and efficacy of this approach Methods Between 2012 and 2015, 72 patients were enrolled in a phase II trial of the CarBiRD regimen for initial treatment of symptomatic NDMM. Patients received Carfilzomib intravenously over 30 minutes on days 1, 2, 8, 9, 15, 16 of a 28 day cycle with Dex 20mg orally on days of Carfilzomib therapy. Carfilzomib was administered at a dose of 20mg/m2 on days 1 and 2 of cycle one of therapy before escalation to target dosing on all subsequent treatment days. The initial protocol was designed with a target Carfilzomib dosing of 45mg/m2, following the enrollment of the first 26 patients on protocol the dosing was increased to 56mg/m2. After maximum response was achieved with Kd, defined as complete response or stable m-protein for 2 consecutive cycles, patients who were eligible for autologous stem cell transplant underwent stem cell collection. Patients then initiated consolidation with Lenalidomide, clarithromycin and Dex (BiRD). BiRD consisted of Lenalidomide 25mg daily on days 1-21 of 28 day cycles, with clarithromycin 500mg twice daily and Dex 40mg on days 1, 8, 15 and 22. BiRD was also continued until achievement of maximum response and patients subsequently initiated maintenance Lenalidomide (Len) at a dose of 10mg on 21 of 28 day cycles. Results 70 out off 72 patients completed at least one cycle of Kd and were evaluated for response. 15 patients came off trial during Carfilzomib therapy: 7 for toxicity, 2 for progression of disease and 6 for either withdrawal of consent, insurance issues or non-compliance. 3 patients came off trial during BiRD consolidation: 1 each for toxicity, progression of disease and withdrawal of consent. The remaining 57 patients initiated BiRD and 54 Len maintenance respectively. Responses are summarized in table 1. The overall response rate was 94% with 84% of patient's achieving a VGPR or better and 37% achieving CR or stringent CR. The rate of CR/sCR increased from 13% (9 of 70 patients) with Kd induction to 28% (16 of 57) with BiRD consolidation and 48% (26 of 54) with Len maintenance. 30% of patients (17 of 57) experience an increased depth of response by at least 1 IMWG response category during BiRD consolidation from their maximum response to Kd. 19% (10 of 54) had an increased depth of response category during Len maintenance. The large majority of adverse events were grade 1 or 2. The most common toxicities across protocol were low-grade gastrointestinal events. The most common grade 3 or higher toxicities were infectious with 17% of patients (12 of 72) experiencing at least one grade 3 or higher infection. Peripheral neuropathy developed in 31% of patients with no grade 3 or higher neuropathy emerging during treatment. The rate of emergent hematologic toxicities was very low across protocol. Discussion CarBiRD is an effective and well-tolerated treatment regimen for patients with NDMM. Using a sequential treatment approach with a highly effective PI and IMiD as the back bones of successive therapies led to high rates of overall response, VGPR or better and complete response in a deferred transplant and transplant ineligible setting.